🔗 Share this article

Given that the US undertakes historic adjustments to its vaccine guidelines, an unexpected name has surfaced in a surprising turn: Høeg, a US-based physician and epidemiologist who first made her name by expressing skepticism about coronavirus shots during the pandemic and has zeroed in on potential deaths following Covid immunization in her brief time at the Food and Drug Administration.

Proposed Changes to Pediatric Vaccine Schedule

Public health authorities had intended to reveal major revisions to the childhood vaccination calendar in December, synchronizing the US with Denmark’s national calendar, according to reports – a significant shift that would place the US out of alignment with many the global community with no evidence for public health gain. This reveal has been delayed until the coming year.

In place of the director of the vaccine center, Tracy Beth Høeg is scheduled to present at the gathering. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the division this year.

A New Direction at the Regulatory Body

The acting appointment could signify a closer partnership between the pharmaceutical and biologics branches as Høeg and Dr. Prasad solidify control at the FDA – and it signals a increased emphasis upon rolling back long-standing immunizations at the FDA.

The new acting director has often pushed for discontinuing certain pediatric shot schedules in the US in order to be more in line with the Danish model, a nation with comprehensive healthcare and a population about the population of the state of Wisconsin.

In her initial comments, she has persisted in emphasizing on vaccines – usually the purview of Prasad, head of the FDA’s vaccine center – instead of drug regulation.

Doubts Over Qualifications

The appointee has no apparent track record in medication creation, approval processes or administrative roles, which has been standard for former heads of the biologics center. She has been employed at the FDA as a key advisor to the commissioner and CBER since March.

“She appears not to have the requisite experience” for overseeing the pharmaceutical oversight division, said Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in managing a sizeable institution. She is not an expert in drug approvals.”

Former commissioners of CBER would “be deeply familiar with legal statutes and the underlying principles of pharmaceutical innovation”, said Dr. Janet Woodcock. “Objectively, she lacks the sort of resume that prior appointees who ran CBER have had.”

CDER has an immense workload at the agency, she emphasized.

“The public just pays attention on the innovative therapies, but the generic program clears numerous off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and so forth, and every single one must be supervised,” she explained. “The responsibility you neglect, that is precisely what that I always told people is going to cause problems.”

Additionally, a substantial management aspect to the position, which manages over 5,000 personnel. “It’s a enormous management job, if you do it right,” Woodcock said.

Official Statement and Contentious Programs

In response to questions about Dr. Høeg's credentials and whether this selection represents more teamwork among FDA leaders on immunizations, a spokesperson said that the “inquiries rely on flawed premises”.

“Her experience matches the responsibilities of her role,” the official said, noting the time Høeg spent counseling the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a controversial one-day therapy clearance system that reportedly troubled her former heads. “By what process are these therapies being chosen for this voucher program? Who makes the choices?” Dr. Howard questioned. “There’s a lot of secrecy going on at the FDA right now.”

Overall, he remarked, “the Food and Drug Administration seems to be moving towards less stringent rules of pharmaceuticals, except for vaccines.”

Established Track Record on Vaccines

Regarding immunizations, Høeg has a more documented, if concerning, track record, some experts said. She released a study using unverified volunteer-provided data to assess the frequency of myocarditis after COVID-19 immunization. She advised the Florida chief medical officer Joseph Ladapo, who allegedly have altered data to suggest Covid vaccines are more dangerous than they are.

Among her “policy goals” for the incoming administration featured changing rules for recently developed shots and discontinuing “optional” immunizations, she said post-election on a audio program. At the FDA, Høeg has reportedly floated the idea of preventing young men from receiving Covid vaccinations.

“She is an complete true believer who begins with her preconceived notions and tailors the evidence to accommodate the data in a very disingenuous, dishonest fashion,” Dr. Howard argued.

Consolidating Power and a “Push for Payback”

Høeg aligned with other dissenters, {like|